Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

3 matching registry records; showing 3 on this page, newest registry updates first. Search checked 2026-10-07 18:05 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableRecruitingINTERVENTIONAL

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

ClinicalTrials.gov · NCT03987308 · Registry updated: 2025-05-02

Condition / research focus: Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM
Sponsor: Beijing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2019-07-02. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug)
Insulin aspart (drug)

Where the study takes place — 16 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Pinggu District Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Capital Medical University Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Emergency General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Peking University Shougang Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting
Harbin Medical University Second Hospital
Harbin, Heilongjiang, China
Site recruitment: Recruiting
Southeast University Zhongda Hospital
Nanjing, Jiangsu, China
Site recruitment: Recruiting
Xuzhou Medical University Affiliated Hospital
Xuzhou, Jiangsu, China
Site recruitment: Recruiting
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Recruiting
Jilin University Second Hospital
Changchun, Jilin, China
Site recruitment: Recruiting
Xi'an Jiaotong University Second Hospital
Xi'an, Shaanxi, China
Site recruitment: Recruiting
Southwest Medical University Affiliated Hospital
Luzhou, Sichuan, China
Site recruitment: Recruiting
Peking University Binhai Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Recruiting
First Hospital of Peking University
Beijing, China
Site recruitment: Recruiting
Heilongjiang provincial hospital
Harbin, China
Site recruitment: Recruiting
Henan People's Hospital
Zhengzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

ClinicalTrials.gov · NCT05005741 · Registry updated: 2023-03-17

Condition / research focus: Diabetes Mellitus, Type 2; Overweight or Obesity
Sponsor: Second Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2021-05-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug) — also listed as: GLP-1 receptor agonist
Dulaglutide (drug) — also listed as: Trulicity, GLP-1 receptor agonist

Where the study takes place — 4 listed sites

Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Site recruitment: Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03829891 · Registry updated: 2022-01-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Xijing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2018-08-07. Completion: 2020-12-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug)
glargine (drug)

Where the study takes place — 2 listed sites

Chang'an Hospital
Xi'an, China,Shanxi, China
Site recruitment: Not reported
Shaanxi Aerospace Hospital
Xi'an, China,Shanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

3 matching registry records; showing 3 on this page, newest registry updates first. Search checked 2026-10-07 18:05 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableRecruitingINTERVENTIONAL

Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients

ClinicalTrials.gov · NCT03987308 · Registry updated: 2025-05-02

Condition / research focus: Type 2 Diabetic Patients; T2DM (Type 2 Diabetes Mellitus); T2DM
Sponsor: Beijing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2019-07-02. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug)
Insulin aspart (drug)

Where the study takes place — 16 listed sites

Pinggu District Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Capital Medical University Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Emergency General Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Peking University Shougang Hospital
Beijing, Beijing Municipality, China
Site recruitment: Recruiting
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting
Harbin Medical University Second Hospital
Harbin, Heilongjiang, China
Site recruitment: Recruiting
Southeast University Zhongda Hospital
Nanjing, Jiangsu, China
Site recruitment: Recruiting
Xuzhou Medical University Affiliated Hospital
Xuzhou, Jiangsu, China
Site recruitment: Recruiting
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
Site recruitment: Recruiting
Jilin University Second Hospital
Changchun, Jilin, China
Site recruitment: Recruiting
Xi'an Jiaotong University Second Hospital
Xi'an, Shaanxi, China
Site recruitment: Recruiting
Southwest Medical University Affiliated Hospital
Luzhou, Sichuan, China
Site recruitment: Recruiting
Peking University Binhai Hospital
Tianjin, Tianjin Municipality, China
Site recruitment: Recruiting
First Hospital of Peking University
Beijing, China
Site recruitment: Recruiting
Heilongjiang provincial hospital
Harbin, China
Site recruitment: Recruiting
Henan People's Hospital
Zhengzhou, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.

ClinicalTrials.gov · NCT05005741 · Registry updated: 2023-03-17

Condition / research focus: Diabetes Mellitus, Type 2; Overweight or Obesity
Sponsor: Second Xiangya Hospital of Central South University
Countries with listed sites: China
Registry dates and results: Start: 2021-05-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug) — also listed as: GLP-1 receptor agonist
Dulaglutide (drug) — also listed as: Trulicity, GLP-1 receptor agonist

Where the study takes place — 4 listed sites

Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Site recruitment: Recruiting
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Site recruitment: Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Site recruitment: Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT03829891 · Registry updated: 2022-01-19

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Xijing Hospital
Countries with listed sites: China
Registry dates and results: Start: 2018-08-07. Completion: 2020-12-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beinaglutide (drug)
glargine (drug)

Where the study takes place — 2 listed sites

Chang'an Hospital
Xi'an, China,Shanxi, China
Site recruitment: Not reported
Shaanxi Aerospace Hospital
Xi'an, China,Shanxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →